Abbott Laboratories vs. Innoviva, Inc. Common Stock
Innoviva, Inc. Common Stock (INVA) comes out ahead, leading on 7 of 11 compared factors.
Size & Scale
| ABT | INVA | |
|---|---|---|
| Market Cap | $175.27 billion | $1.50 billion |
| Revenue (TTM) | $46.59 billion | $440.00 million |
| Net Income (TTM) | $5.42 billion | $357.24 million |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | INVA | |
|---|---|---|
| P/E Ratio | 32.78 | 5.19 |
| Price / Book | 3.39 | 1.21 |
| Price / Sales | 3.76 | 3.41 |
INVA leads on 3 of 3 valuation factors.
Profitability
| ABT | INVA | |
|---|---|---|
| Net Margin | 11.65% | 81.19% |
| Return on Equity | 10.48% | 28.97% |
INVA leads on 2 of 2 profitability factors.
Dividend
| ABT | INVA | |
|---|---|---|
| Dividend Yield | 2.49% | 4.69% |
| Payout Ratio | 81.55 | 24.33 |
INVA leads on 2 of 2 dividend factors.
Risk & Sentiment
| ABT | INVA | |
|---|---|---|
| Short Interest | 0.57% | 19.43% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, INVA overview, INVA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.
